Table 1.
Summary of Study Characteristics
| Study Characteristic | N |
|---|---|
| Country of corresponding author | |
| United States | 23 |
| The Netherlands | 9 |
| United Kingdom | 7 |
| Canada | 6 |
| Australia | 6 |
| Japan | 4 |
| Sweden | 4 |
| Germany, Greece, Iran, Korea, Singapore, Spain | 2 each |
| China, Finland, Lebanon, Malaysia, South Korea, Switzerland, Taiwan, Thailand | 1 each |
| Study design for preference elicitation study | |
| Cross-sectional | 46 |
| Randomized controlled trial | 16 |
| Cohort, prospective | 14 |
| Cohort, retrospective | 3 |
| Respondents | |
| Patients | 56 |
| Public, women | 11 |
| Public | 5 |
| Public, women and patients | 3 |
| Public and patients | 2 |
| Health care professionals | 2 |
| Health utility elicitation method | |
| EQ-5D | 51 |
| SG | 13 |
| TTO | 12 |
| VAS | 10 |
| SF-6D | 4 |
| SHE | 2 |
| TMI | 2 |
| AQOL-4D, 15D, QOL VAS, VR-6D, HALex | 1 each |
AQOL, Australian Quality of Life; SF-6D, HALex, Health and Activities Limitation Index, Short Form-6D; SG, standard gamble; SHE, Subjective Health Estimation; TMI, Testing Morbidities Index; TTO, time tradeoff; QOL, quality of life; VAS, visual analog scale; VR-6D, Veterans RAND-6D.